Company Description
Predictive Oncology Inc., a knowledge and science-driven company, applies artificial intelligence (AI) to support the discovery and development of cancer therapies.
It operates through two segments, Pittsburgh and Eagan. The Pittsburgh segment provides services that include the application of AI using its proprietary biobank of 150,000+ tumor samples.
This segment also creates proprietary 3D culture models used in drug development. Its Eagan segment produces the FDA-cleared STREAMWAY System and associated products for automated medical fluid waste management and patient-to-drain medical fluid disposal.
Predictive Oncology Inc. has a strategic collaboration with Every Cure to identify and prioritize drugs for repurposing.
The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019.
Predictive Oncology Inc. was incorporated in 2002 and is headquartered in Pittsburgh, Pennsylvania.
| Country | United States |
| Founded | 2002 |
| Industry | Health Information Services |
| Sector | Healthcare |
| Employees | 24 |
| CEO | Raymond Vennare |
Contact Details
Address: 91 43rd Street, Suite 110 Pittsburgh, Pennsylvania 15201 United States | |
| Phone | 412 432 1500 |
| Website | predictive-oncology.com |
Stock Details
| Ticker Symbol | POAI |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001446159 |
| CUSIP Number | 74039M408 |
| ISIN Number | US74039M4087 |
| Employer ID | 33-1007393 |
| SIC Code | 3842 |
Key Executives
| Name | Position |
|---|---|
| Raymond F. Vennare | Chief Executive Officer and Chairman |
| Joshua Blacher CPA, M.B.A. | Interim Chief Financial Officer |
| Thomas McLaughlin | Chief Investment Officer |
| Sara Turken J.D. | Senior Vice President and General Counsel |
| Dr. Lawrence J. DeLucas D.Sc, O.D, Ph.D. | Senior Vice President of Biologics |
| Dr. Arlette H. Uihlein FCAP, M.D. | Senior Vice President of Translational Medicine and Drug Discovery and Medical Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 2, 2025 | 8-K | Current Report |
| Nov 25, 2025 | EFFECT | Notice of Effectiveness |
| Nov 25, 2025 | 8-K | Current Report |
| Nov 25, 2025 | 424B3 | Prospectus |
| Nov 24, 2025 | 424B3 | Prospectus |
| Nov 21, 2025 | EFFECT | Notice of Effectiveness |
| Nov 20, 2025 | 8-K | Current Report |
| Nov 20, 2025 | S-3/A | [Amend] Registration statement under Securities Act of 1933 |
| Nov 17, 2025 | 8-K | Current Report |
| Nov 14, 2025 | 8-K | Current Report |